The Norwegian pharmaceutical company Lytix Biopharma today announces the successful completion of two Phase I/IIa studies with the topical antimicrobial drug LytixarTM (LTX-109) – one for nasal decolonisation of MRSA / MSSA (methicillin-resistant and methicillin-sensitive Staphylococcus aureus) bacteria and one for treatment of Gram+ skin infections.
